J&J: development agreement with Pulmatrix
(CercleFinance.com) - Johnson & Johnson has entered into a licensing and development agreement with Pulmatrix, a clinical stage biopharmaceutical company.
Through the agreement, J&J gains an option to access a portfolio of kinase inhibitors intended for development in lung cancer interception.
Under the terms of the agreement, the healthcare giant will make a payment of 7.2 million dollars upfront and an additional 2 million dollars milestone payment upon completion of the ongoing Phase 1b study in stable COPD patients, on-track for year-end 2020.
If J&J exercises its option on the portfolio of these kinase inhibitors, Pulmatrix is eligible for up to 91 million dollars in additional development and commercial milestones, as well as royalty payments.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Through the agreement, J&J gains an option to access a portfolio of kinase inhibitors intended for development in lung cancer interception.
Under the terms of the agreement, the healthcare giant will make a payment of 7.2 million dollars upfront and an additional 2 million dollars milestone payment upon completion of the ongoing Phase 1b study in stable COPD patients, on-track for year-end 2020.
If J&J exercises its option on the portfolio of these kinase inhibitors, Pulmatrix is eligible for up to 91 million dollars in additional development and commercial milestones, as well as royalty payments.
Copyright (c) 2020 CercleFinance.com. All rights reserved.